Jamie Rossjohn elected into the Fellowship of the Academy of Medical Sciences, UK

Monash University scientist, Professor Jamie Rossjohn, has been elected to the Fellowship of the Academy of Medical Sciences in the UK.

The Academy of Medical Sciences Fellows are considered the UK’s leading medical scientists, elected for their contribution to biomedical and health research, the generation of new knowledge in medical sciences and its translation into benefits to society.

Professor Rossjohn, ARC Laureate Fellow, is recognised internationally for his contributions to the field of immunology.

Namely, Rossjohn has provided the basis of key immune recognition events by T cells.  He has shown how T cells recognise polymorphic Human Leukocyte Antigen (HLA) molecules and unearthed mechanisms of HLA polymorphism impacting on drug and food hypersensitivities.  Moreover, he has pioneered our understanding of lipid and metabolite based immunity.

“I am greatly honoured to be invited to join this prestigious academy,” Professor Rossjohn said.

“The Fellowship reflects not only on my work personally but that of my colleagues both at the Biomedicine Discovery Institute and Cardiff University,” he said.

Original article

Monash and Janssen Biotech collaborate on rheumatoid arthritis prevention

Monash University has signed a major multiyear research and commercialisation deal with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the early detection and prevention of rheumatoid arthritis, a debilitating autoimmune disease which affects more than 400,000 Australians1 and more than 24.5 million people worldwide2. The agreement was facilitated by Monash Innovation, part of the recently established Enterprise portfolio at Monash University, and Johnson & Johnson Innovation.

Director of the Monash Biomedicine Discovery Institute, Professor John Carroll, said the collaboration is the result of an existing productive three-year partnership with Janssen and adds to Monash University’s growing international reputation for translational research.

“This exciting strategic partnership is another example of how the Monash BDI’s strong clinical relationships and early industry engagement, are leading to a pipeline of medical breakthroughs,” Professor Carroll said.

The Monash-based researchers, led by ARC Laureate Fellow and Imaging Centre of Excellence Chief Investigator, Professor Jamie Rossjohn, have been investigating the impact of therapeutics on immune systems affected by rheumatoid arthritis.

“This collaboration is a great opportunity to take our advances in basic biomedical science and translate them to the market for the betterment of the Australian population and worldwide,” Professor Rossjohn said.

Original article


Jamie Rossjohn featured in the Australian Financial Review

Janssen Biotech funds Monash rheumatoid arthritis research

Janssen Biotech, part of global giant Johnson & Johnson, has agreed to fund research by a team of scientists led by one of Monash University’s star researchers into rheumatoid arthritis.

The landmark deal means Janssen will have first dibs on new medicines emerging from a research team led by Jamie Rossjohn of Monash’s Biomedicine Discovery Institute that is studying early detection and treatment of the crippling disease suffered by 400,000 Australians and 25 million worldwide.

Original article

Monash secures over AUD $2 million for industry Linkage Projects

Monash University’s innovative, world-leading research and its strong engagement with industry have helped secure significant funding in the latest Australian Research Council (ARC) grants for Linkage Projects.

Monash University has been awarded AUD $2,261,074 to support six applied research projects, ranging from development of a wearable blood-pressure monitor and enhanced inhaler design for more efficient drug delivery, to improved security systems and sequencing DNA to identify the genetics of executive function.

Minister for Education and Training, Senator the Hon. Simon Birmingham, announced the ARC grants for Linkage Projects today (Wednesday 31 May).

Monash Vice-Provost (Research), Professor Pauline Nestor said the funding announcement reflects Monash’s high impact research that has the potential to transform lives.

“From gaining deeper insights into our complex immune systems to enhance treatments for diseases, to boosting the global competitiveness of the Australian security industry by applying mathematics to improve detection systems, our research has the power to respond to some of the world’s greatest challenges and make a real difference,” Professor Nestor said.

“This significant funding for six, diverse ARC Linkage Projects demonstrates the quality and breadth of our applied research as well as our strength in building powerful strategic partnerships with industries and other innovators. I am grateful to the ARC for their continued support and congratulate those talented researchers who have secured Linkage Project funding today.”


Unearthing the basis of Autoimmune Disease

Monash University researchers have discovered the mechanism that explains how key genetic risk factors cause or protect people from autoimmune disease such as type 1 diabetes, multiple sclerosis, and Crohn’s disease.

Monash University researchers have discovered the mechanism that explains how key genetic risk factors cause or protect people from autoimmune disease such as type 1 diabetes, multiple sclerosis, and Crohn’s disease.

Published overnight in Nature, Monash researchers have answered the fundamental question: why, and how, does having different immune molecules change a person’s underlying genetic risk of developing an autoimmune disease?

Original article

Image credit: Vanette Tran.